Tech Company Financing Transactions
Denali Therapeutics Funding Round
On 8/26/2016, Denali Therapeutics raised $130 million in Series B funding from Baillie Gifford and private investors.
Transaction Overview
Company Name
Announced On
8/26/2016
Transaction Type
Venture Equity
Amount
$130,000,000
Round
Series B
Investors
Baillie Gifford (Lead Investor)
Proceeds Purpose
The company will use the funding to fund its drug candidate pipeline.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
161 Oyster Point Blvd.
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Overview
Denali (NASDAQ: DNLI) was founded on the collaboration of leading scientists, industry experts and investors who share the vision that scientific discovery energetically applied to translational medicine is the key to delivering effective therapies to patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ryan Watts
Chief Financial Officer
Steve krognes
Chief Medical Officer
Carole Ho
Chief Operating Officer
Alexander Schuth
VP - Human Resources
Cindy Dunkle
Browse more venture capital transactions:
Prev: 8/26/2016: Grabr venture capital transaction
Next: 8/26/2016: Bitium venture capital transaction
Share this article
Where The Data Comes From
We record tech company VC transactions. VC investment data records on this site come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs